iCAD (ICAD) 10-K 31 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 22, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000749660
Entity Registrant Name	iCAD INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	02-0377419
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, City or Town	Nashua
Entity Address, State or Province	NH
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ICAD
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 92,546,960
Entity Common Stock, Shares Outstanding		25,446,407
Auditor Firm ID	243
Auditor Name	BDO USA, LLP
Auditor Location	Boston, Massachusetts

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 21,313	$ 34,282
Trade accounts receivable, net of allowance for doubtful accounts of $922 in 2022 and $268 in 2021	8,898	8,891
Inventory, net	5,389	4,171
Prepaid expenses and other current assets	2,641	2,962
Total current assets	38,241	50,306
Property and equipment:
Equipment	3,076	7,121
Leasehold improvements	110	172
Furniture and fixtures	23	319
Marketing assets	0	376
Property, Plant and Equipment, Gross, Ending Balance	3,209	7,988
Less accumulated depreciation and amortization	2,135	7,106
Property and equipment, net	1,074	882
Other assets:
Operating lease assets	3,361	1,059
Other assets	69	899
Intangible assets, net of accumulated amortization of $8,932 in 2022 and $8,724 in 2021	482	683
Goodwill	8,362	8,362
Deferred tax assets	116	0
Total other assets	12,390	11,003
Total assets	51,705	62,191
Current liabilities:
Accounts payable	1,973	2,779
Accrued and other expenses	4,681	5,642
Lease payable, current	582	889
Deferred revenue, current	6,216	5,652
Total current liabilities	13,452	14,962
Lease payable, long-term	2,803	266
Deferred revenue, long-term	542	441
Deferred tax	6	5
Total liabilities	16,803	15,674
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.	0	0
Common stock, $ .01 par value: authorized 60,000,000 shares; issued 25,446,407 in 2022 and 25,326,086 in 2021. Outstanding 25,260,576 in 2022 and 25,140,255 in 2021	254	253
Additional paid-in capital	302,899	300,859
Accumulated deficit	(266,836)	(253,180)
Treasury stock at cost, 185,831 shares in 2022 and 2021	(1,415)	(1,415)
Total stockholders’ equity	34,902	46,517
Total liabilities and stockholders’ equity	$ 51,705	$ 62,191

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts on trade accounts receivable	$ 922	$ 268
Intangible assets, accumulated amortization	$ 8,932	$ 8,724
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	25,446,407	25,326,086
Common stock, shares outstanding (in shares)	25,260,576	25,140,255
Treasury stock, shares (in shares)	185,831	185,831

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Revenue	$ 27,944	$ 33,638	$ 29,698
Cost of Revenue:
Cost of revenue	8,132	9,395	8,344
Gross profit	19,812	24,243	21,354
Operating expenses:
Engineering and product development	8,593	9,194	8,114
Marketing and sales	13,691	15,135	13,312
General and administrative	11,234	10,406	9,117
Amortization and depreciation	224	240	199
Total operating expenses	33,742	34,975	30,742
Loss from operations	(13,930)	(10,732)	(9,388)
Other income (expense)
Interest expense	(10)	(141)	(476)
Interest income	213	15	97
Loss on extinguishment of debt	0	(386)	(341)
Loss on fair value of convertible debentures	0	0	(7,464)
Other	(45)	0	0
Other income (expense), net	158	(512)	(8,184)
Loss before income tax expense	(13,772)	(11,244)	(17,572)
Benefit (provision) for income taxes	116	(1)	(38)
Net loss and comprehensive loss	$ (13,656)	$ (11,245)	$ (17,610)
Net loss per share:
Basic (in dollars per share)	$ (0.54)	$ (0.45)	$ (0.80)
Diluted (in dollars per share)	$ (0.54)	$ (0.45)	$ (0.80)
Weighted average number of shares used in computing net loss per share:
Basic (in shares)	25,202	24,778	22,140
Diluted (in shares)	25,202	24,778	22,140
Product [Member]
Revenue:
Revenue	$ 15,398	$ 21,191	$ 18,903
Cost of Revenue:
Cost of revenue	5,852	5,653	5,000
Service and Supplies [Member]
Revenue:
Revenue	12,546	12,447	10,795
Cost of Revenue:
Cost of revenue	1,983	3,425	2,965
Amortization and Depreciation [Member]
Cost of Revenue:
Cost of revenue	$ 297	$ 317	$ 379

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2019	19,546,151
Balance at Dec. 31, 2019	$ 196	$ 230,615	$ (224,325)	$ (1,415)	$ 5,071
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations (in shares)	97,830
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations	$ 0	(225)	0	0	(225)
Issuance of common stock pursuant to stock option plans (in shares)	155,149
Issuance of common stock pursuant to stock option plans	$ 1	728	0	0	729
Issuance of common stock, net (in shares)	2,033,204
Issuance of common stock, net	$ 20	18,264	0	0	18,284
Issuance of common stock pursuant employee stock purchase plan (in shares)	42,606
Issuance of common stock pursuant employee stock purchase plan	$ 1	267	0	0	268
Issuance of common stock upon conversion of debentures (in shares)	1,819,466
Issuance of common stock upon conversion of debentures	$ 18	21,146	0	0	21,164
Stock-based compensation	0	2,844	0	0	2,844
Net loss	$ 0	0	(17,610)	0	(17,610)
Balance (in shares) at Dec. 31, 2020	23,694,406
Balance at Dec. 31, 2020	$ 236	273,639	(241,935)	(1,415)	30,525
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations (in shares)	44,706
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations	$ 1	(60)	0	0	$ (59)
Issuance of common stock pursuant to stock option plans (in shares)	168,450				168,450
Issuance of common stock pursuant to stock option plans	$ 2	1,025	0	0	$ 1,027
Issuance of common stock, net (in shares)	1,393,738
Issuance of common stock, net	$ 14	23,215	0	0	23,229
Issuance of common stock pursuant employee stock purchase plan (in shares)	24,786
Issuance of common stock pursuant employee stock purchase plan	$ 0	257	0	0	257
Stock-based compensation	0	2,783	0	0	2,783
Net loss	$ 0	0	(11,245)	0	(11,245)
Balance (in shares) at Dec. 31, 2021	25,326,086
Balance at Dec. 31, 2021	$ 253	300,859	(253,180)	(1,415)	46,517
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations (in shares)	725
Issuance of common stock relative to vesting of restricted stock, net of shares forfeited for tax obligations	$ 0	0	0	0	$ 0
Issuance of common stock pursuant to stock option plans (in shares)	73,500				73,500
Issuance of common stock pursuant to stock option plans	$ 1	206	0	0	$ 207
Issuance of common stock pursuant employee stock purchase plan (in shares)	46,096
Issuance of common stock pursuant employee stock purchase plan	$ 0	148	0	0	148
Stock-based compensation	0	1,686	0	0	1,686
Net loss	$ 0	0	(13,656)	0	(13,656)
Balance (in shares) at Dec. 31, 2022	25,446,407
Balance at Dec. 31, 2022	$ 254	$ 302,899	$ (266,836)	$ (1,415)	$ 34,902

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares forfeited for tax obligations (in shares)	150	5,196	20,247

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flow from operating activities:
Net loss	$ (13,656)	$ (11,245)	$ (17,610)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	211	230	309
Depreciation	310	327	268
Non-cash lease expense	708	778	752
Bad debt provision	732	167	94
Stock-based compensation expense	1,686	2,783	2,844
Amortization of debt discount and debt costs	0	17	78
Loss on extinguishment of debt	0	386	341
Deferred tax	(116)	1	1
Loss on disposal of assets	0	97	0
Change in fair value of convertible debentures	0	0	7,464
Other, net	9	0	0
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(739)	969	(302)
Inventory	(1,218)	(1,027)	(533)
Prepaid and other assets	1,152	391	(1,390)
Accounts payable	(806)	(90)	878
Accrued and other expenses	(961)	(2,123)	(207)
Lease liabilities	(767)	(778)	(752)
Deferred revenue	665	(291)	780
Total adjustments	866	1,837	10,625
Net cash used for operating activities	(12,790)	(9,408)	(6,985)
Cash flow used for investing activities:
Additions to patents, technology and other	(10)	(24)	(13)
Additions to property and equipment	(524)	(563)	(461)
Net cash used for investing activities	(534)	(587)	(474)
Cash flow from financing activities:
Issuance of common stock for cash, net	0	23,229	18,285
Issuance of common stock pursuant to Employee Stock Purchase Plan	148	257	266
Issuance of common stock pursuant to stock option plans	207	1,027	729
Taxes paid related to restricted stock issuance	0	(59)	(225)
Proceeds from notes payable	0	0	6,957
Principal repayment of notes payable	0	(7,363)	(4,638)
Debt issuance costs	0	0	(42)
Proceeds from line of credit	0	0	775
Repayment of line of credit	0	0	(2,775)
Net cash provided by financing activities	355	17,091	19,332
Increase in cash and cash equivalents	(12,969)	7,096	11,873
Cash and cash equivalents, beginning of year	34,282	27,186	15,313
Cash and cash equivalents, end of year	21,313	34,282	27,186
Supplemental disclosure of cash flow information:
Interest paid	9	172	272
Taxes paid	0	0	38
Right-of-use assets obtained in exchange for new operating lease liabilities	3,011	79	69
Issuance of common stock upon conversion of debentures	$ 0	$ 0	$ 21,164

Note 1 - Organization and Busin

Note 1 - Organization and Business	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Organization and Business iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a global medical technology company providing innovative cancer detection and therapy solutions. The Company operates in two third 14 The Company maintains its headquarters and a separate manufacturing facility in Nashua, New Hampshire, an operations, research, development, manufacturing and warehousing facility in San Jose, California, and an office in Lyon, France.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation. Risk and Uncertainty On March 12, 2020, 19 19, December 31, 2022, 19 In late February 2022, December 31, 2022 may may may not 2022, Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 may $250,000 4 not not December 31, 2022, not Financial instruments Financial instruments consist of cash and cash equivalents, trade accounts receivable, contract assets, accounts payable, accrued and other expenses and notes payable. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2022 2021 Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are initially established through a process of reviewing the financial history and stability of each customer and the Company performs continuing credit evaluations of its customers’ financial condition and generally does not December 31, 2022 2023 The Company’s policy is to maintain allowances for potential losses resulting from the inability of a portion of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may may December 31, 2022 2021 Inventory The Company uses the first first Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which is generally three five Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350 20, “Intangibles Goodwill and Other 350 20” not Factors the Company considers important, which could trigger an impairment of Goodwill, include the following: • significant and sustained underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the Company’s assets in the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant and sustained decline in the Company’s stock price; and • a decline in the Company’s market capitalization below net book value. The two The Company records an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of its annual measurement date, judgment is required in determining whether an event has occurred that may Fair values for the reporting units are based on a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as the fact that market data may not may The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to our business profile, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. Equally important, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not The Company performed the annual impairment assessment at October 1, 2022 Long Lived Assets In accordance with FASB ASC Topic 360, 360” not ASC 360 10 35 no 360 10 35 21 may not • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); • significant and sustained decline in the Company’s stock price. In accordance with ASC 360 10 35 17, not The Company did not December 31, 2022 December 31, 2021 Intangible assets subject to amortization consist primarily of patents, technology intangibles, trade names, customer relationships and distribution agreements purchased in the Company’s previous acquisitions. These assets are amortized on a straight-line basis or the pattern of economic benefit over their estimated useful lives of 5 to 10 years. Leases In accordance with FASB ASC Topic 842, 842" At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an extension option if the Company is reasonably certain to exercise that option. Right-of-use assets and obligations for leases with an initial term of 12 not not third not 606, 606" ASC 842 no December 31, 2022 Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease components that transfer a distinct service to the Company, such as common area maintenance services. The Company has elected to separate the accounting for lease components and non-lease components for real estate and equipment leases. Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company grants to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may not 718, “Compensation Stock Compensation 718” The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, and the number of options that will be forfeited prior to the completion of their vesting requirements. The Company estimates forfeitures based on historical experience with pre-vested forfeitures. To the extent actual forfeitures differ from the estimate, the difference is recorded to compensation expense in the period of the forfeiture. Fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations. Revenue Recognition In accordance with ASC 606, five 1 Identify the contract(s) with a customer may not 2 Identify the performance obligations in the contract third not not one 3 Determine the transaction price not 4 Allocate the transaction price to the performance obligations in the contract not 5 Recognize revenue when (or as) the Company satisfies a performance obligation The Company recognizes revenue from its contracts with customers primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when control of the promised goods or services is transferred to a customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. For iCAD’s typical product revenue, control typically transfers upon shipment as title and risk of loss have passed to the customer. Services and supplies are considered to be transferred as the services are performed or over the term of the service or supply agreement. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Perpetual software licenses are accounted for as a single performance obligation and revenue is recognized at the point in time when ownership is transferred to the customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of revenue. The Company continues to provide for estimated warranty costs on original product warranties at the time of sale. Goods and Services Classifications Products Service Contracts 12 48 Supply and Source Usage Agreements Professional Services Other Significant Judgments The Company’s contracts with customers may may one may The Company may not Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes incremental costs of obtaining a contract with a customer as an asset if the Company expects the benefit of those costs to be longer than one one Right to Invoice Where applicable, the Company recognizes revenue from a contract with a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date and the amount to which the Company has a right to invoice. Sales and Other Similar Taxes The Company excludes sales taxes and similar taxes from the measurement of transaction price and ensures compliance with the disclosure requirements of ASC 235. Significant Financing Component The Company does not one Promised Goods or Services that are Immaterial in the Context of a Contract The Company assesses materiality of promised goods or services as performance obligations in the context of a contract and the Company does not 606 The Company does not one Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house product warranty repairs, amortization of acquired technology and any applicable medical device tax. Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty costs have not Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials are expensed as incurred. Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2022, 2021 2020 Income Taxes The Company follows the liability method under ASC Topic 740 Income Taxes 740” 740 December 31, 2022 December 31, 2021, December 31, 2022, not December 31, 2021, 13

Note 3 - Recently Issued Accoun

Note 3 - Recently Issued Accounting Standards	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	Note 3 Recently Issued Accounting Standards In June 2016, 2016 13, 326 2016 13” 2016 13 November 2019, 2016 13 December 15, 2022. 2016 13 2016 13 January 1, 2023. twelve 2016 13 not In December 2019, 2019 12, 740 2019 12” 2019 12 740. 740 2019 12 January 1, 2021. 2019 12 no

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4 Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, Fair Value Measurement and Disclosures 820” three first two • Level 1 • Level 2 1 not • Level 3 no The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying balance sheet are considered a Level 1 The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousand): Fair Value Measurements (in thousands) as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,067 $ — $ — $ 15,067 Total Assets $ 15,067 $ — $ — $ 15,067 Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573 There were no Level 3 December 31, 2022 December 31, 2021 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. There were no items measured at fair value on a nonrecurring basis as of or during the years ended December 31, 2022 2021

Note 5 - Revenue

Note 5 - Revenue	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5 Revenue Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition and sales channel, reconciled to its reportable segments (in thousands). Year ended December 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 12,492 $ 2,777 $ 15,269 Service contracts 7,310 1,540 8,850 Supply and source usage agreements — 1,643 1,643 Disposable applicators — 1,776 1,776 Professional services and other — 406 406 $ 19,802 $ 8,142 $ 27,944 Timing of Revenue Recognition Goods transferred at a point in time $ 12,545 $ 4,969 $ 17,514 Services transferred over time 7,257 3,173 10,430 $ 19,802 $ 8,142 $ 27,944 Sales Channels Direct sales force $ 12,468 $ 3,543 $ 16,011 OEM partners 7,334 — 7,334 Channel partners — 4,599 4,599 $ 19,802 $ 8,142 $ 27,944 Year ended December 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 15,661 $ 5,530 $ 21,191 Service contracts 6,358 1,608 7,966 Supply and source usage agreements — 2,340 2,340 Disposable applicators — 1,810 1,810 Professional services and other — 331 331 $ 22,019 $ 11,619 $ 33,638 Timing of Revenue Recognition Goods transferred at a point in time $ 15,584 $ 8,012 $ 23,596 Services transferred over time 6,435 3,607 10,042 $ 22,019 $ 11,619 $ 33,638 Sales Channels Direct sales force $ 14,713 $ 4,421 $ 19,134 OEM partners 7,306 — 7,306 Channel partners — 7,198 7,198 $ 22,019 $ 11,619 $ 33,638 Year ended December 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,291 $ 4,535 $ 20,826 Service contracts 5,661 1,333 6,994 Supply and source usage agreements — 1,804 1,804 Professional services — 29 29 Other 45 — 45 $ 21,997 $ 7,701 $ 29,698 Timing of Revenue Recognition Goods transferred at a point in time $ 16,332 $ 4,624 $ 20,956 Services transferred over time 5,665 3,077 8,742 $ 21,997 $ 7,701 $ 29,698 Sales Channels Direct sales $ 13,809 $ 3,773 $ 17,582 OEM partners 8,188 — 8,188 Channel partners — 3,928 3,928 $ 21,997 $ 7,701 $ 29,698 Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current contract assets are a component of other assets. The following table provides information about receivables, current and non-current contract assets, and contract liabilities from contracts with customers (in thousands). Balance at December 31, 2022 Balance at December 31, 2021 Receivables, which are included in ‘Trade accounts receivable’ $ 8,898 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 759 $ 1,895 Non-current contract assets, which are included in “other assets” $ 15 $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,758 $ 6,093 The Company records a receivable when revenue is recognized prior to receipt of cash payments and the Company has the unconditional right to such consideration, or deferred revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract basis. The Company records a contract asset for unbilled revenue when the Company’s performance exceeds amounts billed or billable. The Company classifies the net contract asset as either current or non-current based on the expected timing of the Company’s right to bill under the terms of the contract. The current contract asset balance primarily relates to the net unbilled revenue balances with two one two one Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally billed in advance. Deferred revenue also includes payments for installation and training that has not Changes in deferred revenue from contracts with customers were as follows (in thousands): Year Ended December 31, 2022 Year Ended December 31, 2021 Balance at beginning of period $ 6,093 $ 6,384 Deferral of revenue 12,129 12,315 Recognition of deferred revenue (11,464 ) (12,606 ) Balance at end of period $ 6,758 $ 6,093 The Company expects to recognize estimated revenues related to performance obligations that are unsatisfied (or partially satisfied) in the amounts of approximately $4.0 million in 2023, 2024, 2025. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if it expects the benefit of those costs to be longer than one December 31, 2022 2021 Changes in the balance of capitalized costs to obtain a contract were as follows (in thousands): Years Ended December 31, 2022 2021 Balance at beginning of period $ 302 $ 406 Deferral of costs to obtain a contract 120 249 Recognition of costs to obtain a contract (181 ) (353 ) Balance at end of period $ 241 $ 302

Note 6 - Net Loss Per Common Sh

Note 6 - Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6 Net Loss per Common Share The Company follows FASB ASC 260 10, “Earnings per Share” A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2022 2021 2020 Net loss $ (13,656 ) $ (11,245 ) $ (17,610 ) Basic shares used in the calculation of earnings per share 25,202 24,778 22,140 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 25,202 24,778 22,140 Net loss per share: Basic $ (0.54 ) $ (0.45 ) $ (0.80 ) Diluted $ (0.54 ) $ (0.45 ) $ (0.80 ) The following table summarizes the number of shares of common stock for convertible securities, warrants and restricted stock that were not Year Ended December 31, 2022 2021 2020 Common stock options 2,610,659 2,486,511 1,869,507 Restricted Stock — 875 29,166 2,610,659 2,487,386 1,898,673 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not

Note 7 - Allowance for Doubtful

Note 7 - Allowance for Doubtful Accounts	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Allowance for Credit Losses [Text Block]	Note 7 Allowance for Doubtful Accounts The rollforward of the Company’s allowance for doubtful accounts for the years ended December 31 2022 2021 2020 Balance at beginning of period $ 268 $ 111 $ 136 Additions charged to costs and expenses 732 167 94 Reductions (78 ) (10 ) (119 ) Balance at end of period $ 922 $ 268 $ 111

Note 8 - Inventories

Note 8 - Inventories	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 8 Inventories Inventory balances at December 31, 2022 2021 December 31, 2022 December 31, 2021 Raw materials $ 2,658 $ 2,962 Work in process 101 173 Finished Goods 2,892 1,279 Inventory Gross 5,651 4,414 Inventory Reserve (262 ) (243 ) Inventory Net $ 5,389 $ 4,171

Note 9 - Goodwill and Intangibl

Note 9 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 9 Goodwill and Intangible assets At December 31, 2022 2021 December 31, 2022 2021 Amortization expense related to intangible assets was approximately $211,000, $230,000 and $309,000 for the years ended December 31, 2022, 2021 2020 Weighted average useful life 2022 2021 2020 (in years) Gross Carrying Amount Patents and licenses $ 626 $ 619 $ 595 5 Technology 8,257 8,257 8,257 10 Customer relationships 272 272 272 7 Tradename 259 259 259 10 Total amortizable intangible assets 9,414 9,407 9,383 Accumulated Amortization Patents and licenses $ 537 $ 534 $ 529 Technology 7,947 7,769 7,571 Customer relationships 189 162 135 Tradename 259 259 259 Total accumulated amortization 8,932 8,724 8,494 Total amortizable intangible assets, net $ 482 $ 683 $ 889 Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): Estimated For the years ended amortization December 31: expense 2023 206 2024 121 2025 119 2026 18 2027 18 $ 482

Note 10 - Accrued and Other Exp

Note 10 - Accrued and Other Expenses	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 10 Accrued and Other expenses Accrued and other expenses consist of the following at December 31 2022 2021 Accrued salary and related expenses $ 1,248 $ 2,016 Accrued accounts payable 2,913 2,838 Accrued professional fees 400 497 Other accrued expenses 120 291 $ 4,681 $ 5,642

Note 11 - Leases

Note 11 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 11 Leases The Company has leases for office space and office equipment. The leases expire at various dates through 2028. May 2022, November 2022, October 2021, 2024, Year Ended December 31, Lease Cost Classification 2022 2021 Operating lease cost - Right of Use Operating expenses $ 859 $ 862 Operating lease cost - Variable Costs Operating expenses 277 186 Total $ 1,136 $ 1,048 Year Ended December 31, 2022 2021 Cash paid for operating cash flows from operating leases $ 931 $ 919 As of December 31, 2022 2021 Weighted-average remaining lease term of operating leases (in years) 3.77 1.33 Weighted-average discount rate for operating leases 6.98 % 5.50 % Maturities of the Company’s lease liabilities as of December 31, 2022 Year Ended December 31: Total 2023 781 2024 846 2025 848 2026 749 2027 685 Thereafter 172 Total lease payments 4,081 Less: effects of discounting (696 ) Total lease liabilities 3,385 Less: current portion of lease liabilities (582 ) Long-term lease liabilities $ 2,803

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 12 Stockholders Equity (a) Financing Activity On April 27, 2020, December 17, 2020 March 2, 2021, On March 2, 2021, March 5, 2021. (b) Stock Options The Company's 2016 “2016 may 2016 not may At the Company’s 2021 2016 December 31, 2022 2016 Weighted Average Remaining Number of Weighted Average Contractual Term Shares Exercise Price (in years) Outstanding, December 31, 2020 1,869,507 $ 5.91 Granted 865,938 $ 16.33 Exercised (168,450 ) $ 6.10 Forfeited (80,484 ) $ 13.74 Outstanding, December 31, 2021 2,486,511 $ 9.27 5.42 Granted 836,500 $ 4.92 Exercised (73,500 ) $ 2.45 Forfeited (638,519 ) $ 11.45 Outstanding, December 31, 2022 2,610,992 $ 7.54 3.76 Exercisable at December 31, 2020 1,540,287 $ 5.55 Exercisable at December 31, 2021 1,619,855 $ 6.47 Exercisable at December 31, 2022 1,906,189 $ 7.59 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenue $ 3 $ 15 $ 30 Engineering and product development 220 356 376 Marketing and sales 518 785 657 General and administrative expense 945 1,627 1,781 $ 1,686 $ 2,783 $ 2,844 As of December 31, 2022 Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Year Ended December 31, 2022 2021 2020 Average risk-free interest rate 2.29 % 0.42 % 0.65 % Expected dividend yield None None None Expected life (in years) 3.5 3.5 3.5 Expected volatility 66.30 - 72.04 % 65.57 - 67.42 % 50.17 - 66.04 % Weighted average fair value $ 2.33 $ 7.22 $ 4.37 The Company’s 2022 2021 2020 zero no not Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Intrinsic value of stock options Year Ended December 31, 2022 2021 2020 Outstanding $ — $ 3,820 $ 13,626 Exercisable $ — $ 3,730 $ 11,786 Exercised $ — $ 1,453 $ 1,037 Company’s stock price at December 31 $ 1.83 $ 7.20 $ 13.20 As of December 31, 2022, zero (c) Restricted Stock The Company’s restricted stock awards typically vest in either one three first one 2021 2020 A summary of unvested restricted stock activity for the Stock Plans is follows: Year Ended December 31, 2022 2021 2020 Beginning outstanding balance 875 29,166 150,909 Granted — 22,488 — Vested (875 ) (50,779 ) (118,077 ) Forfeited — — (3,666 ) Ending outstanding balance — 875 29,166 (d) Employee Stock Purchase Program: In December 2019, 2019 January 1, 2020. may Substantially all of the Company’s employees whose customary employment is for more than 20 Any eligible employee can enroll in the Plan as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may first no may The Company issued 46,096 and 24,786 shares of common stock under the ESPP for the years ended December 31, 2022 2021 December 31, 2022 October 2022, October 1, 2022 December 31, 2022 not

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 13 Income Taxes Income Taxes The components of income tax expense for the years ended December 31 2022 2021 2020 Current provision: Federal $ — $ — $ — State — — 37 Foreign — — — $ — $ — $ 37 Deferred provision: Federal $ — $ 1 $ 1 State — — — Foreign (116 ) — — $ (116 ) $ 1 $ 1 Total $ (116 ) $ 1 $ 38 The Company adopted ASU 2019 12 January 1, 2021. December 31, 2020 not 2019 12 A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 2.5 % 5.2 % 2.4 % Net state impact of deferred rate change (1.0 )% 0.8 % (0.7 )% Stock compensation expense (0.7 )% 1.3 % 0.9 % Other permanent differences (0.4 )% (0.1 )% (0.1 )% Change in valuation allowance (13.7 )% (24.4 )% (13.4 )% Tax credits 2.0 % 3.1 % 1.4 % Accrual to tax return 0.0 % (1.4 )% 0.0 % FV Mark to market on convertible notes 0.0 % 0.0 % (9.0 )% Foreign Rate Differential 0.0 % 0.0 % 0.0 % True Ups - NOL Expiration/162(m) limits (8.9 )% (5.4 )% (2.8 )% Effective income tax 0.8 % 0.1 % (0.3 )% Deferred tax assets and liabilities are recognized for the expected future tax consequences of net operating loss carryforwards, tax credit carryforwards and temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not not Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. The Company has fully reserved the U.S. net deferred tax assets, as it is more likely than not not not not December 31, 2022 2021 2022 2021 Inventory (Section 263A) $ 311 $ 276 Inventory reserves 61 61 Bad debt reserves 215 67 Other accruals 813 854 Deferred revenue 129 107 Accumulated depreciation/amortization 17 8 Stock options 1,108 795 Developed technology 976 1,242 Tax credits 4,427 4,176 NOL carryforward 38,234 38,383 Lease Liability 792 — Section 174 R&D 1,749 290 Deferred tax assets 48,832 46,259 Valuation allowance (47,930 ) (45,994 ) Right of Use Asset (786 ) (265 ) Goodwill tax amortization (6 ) (5 ) Net deferred tax asset (liability) $ 110 $ (5 ) The increase in the net deferred tax assets and corresponding valuation allowance during the year ended December 31, 2022 174 December 31, 2021 As of December 31, 2022, 2023 2037. December 31, 2017 December 31, 2022, December 31, 2022, December 31, 2022, not may The Company currently has approximately $4.6 million in net operating losses that are subject to limitations related to Xoft. Approximately $656,000 can be used annually through 2029. 1986 2042. no 2030. ASC 740 10 As of December 31, 2022 2021 no 740 10. zero December 31, 2022, 2021 2020 three not The Company does not December 31, 2022 12

Note 14 - Segment Reporting

Note 14 - Segment Reporting	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 14 Segment Reporting (a) Segment Reporting Operating segments are the components of our business for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is our chief executive officer. Our operating segments are generally organized by the type of product or service offered and by geography. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no The Company does not not Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Segment revenues: Detection $ 19,802 $ 22,019 $ 21,997 Therapy 8,142 11,619 7,701 Total Revenue $ 27,944 $ 33,638 $ 29,698 Segment gross profit: Detection $ 16,824 $ 18,510 $ 17,856 Therapy 2,988 5,733 3,498 Total gross profit $ 19,812 $ 24,243 $ 21,354 Segment operating income (loss): Detection $ 902 $ 1,563 $ 2,719 Therapy (3,767 ) (1,835 ) (3,028 ) Segment operating income (loss) $ (2,865 ) $ (272 ) $ (309 ) General administrative $ (10,852 ) $ (10,460 ) $ (9,079 ) Interest expense (10 ) (141 ) (476 ) Loss on extinguishment of debt — (386 ) (341 ) Other income (45 ) 15 97 Fair value of convertible debentures — — (7,464 ) Loss before income tax $ (10,907 ) $ (10,972 ) $ (17,263 ) Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Detection depreciation and amortization Depreciation $ 109 $ 123 $ 115 Amortization $ 134 $ 158 164 Therapy depreciation and amortization Depreciation $ 129 $ 129 $ 124 Amortization $ 73 $ 73 128 (b) Geographic Information The Company’s sales are made to customers, distributors and dealers of mammography, electronic brachytherapy equipment and other medical equipment, and to foreign distributors of mammography and electronic brachytherapy equipment. Export revenue to a single country did not 10% 2022 2021 2020 As of December 31, 2022 2021 Percent of Export sales Region 2022 2021 2020 Europe 24 % 39 % 45 % Taiwan 14 % 12 % 13 % Israel 13 % 0 % 0 % Bangladesh 8 % 0 % 0 % Malaysia 4 % 0 % 0 % Canada 1 % 3 % 5 % China 18 % 35 % 22 % Australia 3 % 0 % 0 % Other 15 % 11 % 15 % Total 100 % 100 % 100 % Total Export Revenue $ 6,976 $ 7,527 $ 6,081 Significant export sales in Europe are as follows: Percent of Export sales Region 2022 2021 2020 France 45 % 47 % 41 % Italy 11 % 5 % 8 % Spain 10 % 17 % 17 % Germany 9 % 4 % 12 % Belgium 8 % 0 % 0 % Switzerland 6 % 8 % 0 % Sweden 4 % 0 % 0 % United Kingdom 1 % 4 % 6 % Russia 0 % 8 % 0 % % % % % % % (c) Major Customers The Company had one 2022 2021 2020 December 31, 2022 four December 31, 2022 December 31, 2021 December 31, 2020 one December 31, 2022 OEM partners represented $2.0 million or 22% of outstanding receivables as of December 31, 2022 four December 31, 2022 December 31, 2022 40%of December 31, 2022

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 15 Commitments and Contingencies (a) Purchase Commitments The Company has non-cancelable purchase orders with key suppliers executed in the normal course of business that total approximately $4.6 million. (b) Employment Agreements The Company has entered into employment agreements with certain executives and key employees. The employment agreements provide for minimum severance payments and performance-based annual bonus compensation, as defined in their respective agreements, in the event that their employment is terminated without cause. (c) Royalty Obligations In connection with prior litigation, the Company received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not 2016. four (d) Legal Matters In December 2016, January 30, 2017 On September 5, 2018, third No. 1:18 08083 April 13, 2021, one second 2021. In addition to the foregoing, the Company may no may not 450,

Note 16 - Notes Payable

Note 16 - Notes Payable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 16 Notes Payable (a) Loan and Security Agreement Western Alliance Bank On March 30, 2020, On April 27, 2021, (b) Loan and Security Agreement Silicon Valley Bank On August 7, 2017, On March 30, 2020, March 2020 (c) Convertible Debentures On December 20, 2018, not On February 21, 2020 As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make-whole provisions in the Convertible Debentures, the Company also issued an additional 76,966 shares of its common stock. The make-whole amount represented the total interest which would have accrued through the maturity date of the Convertible Debentures, less the amounts previously paid, totaling $697,000. The conversion prices related to the make-whole amount were dependent on whether the Investors were related parties or unrelated third Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures The Company had previously elected to make a one The Company recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% The Company notes that the key inputs to the simulation model that were utilized to estimate the fair value of the Convertible Debentures at each valuation date included: Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 — Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A Probability of default event 1 0.45 % N/A Utilization of Forced Conversion (if available) 1 100.00 % 100.00 % Exercise of Default Redemption (if available) 1 100.00 % N/A Effective discount rate 1 18.52 % N/A 1 Represents a Level 3 4 The Company’s stock price is based on the closing stock price on the valuation date. The conversion price is based on the contractual conversion price included in the SPA. The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures. The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of comparable guideline public companies. The risk-free rate was determined based on U.S. Treasury securities with similar terms. The probability of the occurrence of a default event was based on Bloomberg’s one The utilization of the Forced Conversion right and the default redemption right is based on management’s best estimate of both features being exercised upon the occurrence of the related contingent events. The effective discount rate utilized at the December 31, 2019 February 21, 2020 December 31, 2019 no The fair value and principal value of the Convertible Debentures as of December 31, 2019 Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970 The Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for the year ending December 31, 2020.

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Defined Benefit Plan [Text Block]	Note 17 Employee Benefit Plan The Company has a 401 “401 may 401 not December 31, 2022 2021

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	18 Subsequent Events On March 20, 2023, one first 2023 one may 2023. The Company has evaluated all other events and transactions subsequent to the balance sheet date to the date of filing and is not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risk and Uncertainty On March 12, 2020, 19 19, December 31, 2022, 19 In late February 2022, December 31, 2022 may may may not 2022,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 may $250,000 4 not not December 31, 2022, not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial instruments Financial instruments consist of cash and cash equivalents, trade accounts receivable, contract assets, accounts payable, accrued and other expenses and notes payable. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2022 2021
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are initially established through a process of reviewing the financial history and stability of each customer and the Company performs continuing credit evaluations of its customers’ financial condition and generally does not December 31, 2022 2023 The Company’s policy is to maintain allowances for potential losses resulting from the inability of a portion of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may may December 31, 2022 2021
Inventory, Policy [Policy Text Block]	Inventory The Company uses the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which is generally three five
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350 20, “Intangibles Goodwill and Other 350 20” not Factors the Company considers important, which could trigger an impairment of Goodwill, include the following: • significant and sustained underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the Company’s assets in the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant and sustained decline in the Company’s stock price; and • a decline in the Company’s market capitalization below net book value. The two The Company records an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of its annual measurement date, judgment is required in determining whether an event has occurred that may Fair values for the reporting units are based on a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as the fact that market data may not may The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to our business profile, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. Equally important, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not The Company performed the annual impairment assessment at October 1, 2022
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long Lived Assets In accordance with FASB ASC Topic 360, 360” not ASC 360 10 35 no 360 10 35 21 may not • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group); • significant and sustained decline in the Company’s stock price. In accordance with ASC 360 10 35 17, not The Company did not December 31, 2022 December 31, 2021 Intangible assets subject to amortization consist primarily of patents, technology intangibles, trade names, customer relationships and distribution agreements purchased in the Company’s previous acquisitions. These assets are amortized on a straight-line basis or the pattern of economic benefit over their estimated useful lives of 5 to 10 years.
Lessee, Leases [Policy Text Block]	Leases In accordance with FASB ASC Topic 842, 842" At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an extension option if the Company is reasonably certain to exercise that option. Right-of-use assets and obligations for leases with an initial term of 12 not not third not 606, 606" ASC 842 no December 31, 2022 Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease components that transfer a distinct service to the Company, such as common area maintenance services. The Company has elected to separate the accounting for lease components and non-lease components for real estate and equipment leases.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company grants to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may not 718, “Compensation Stock Compensation 718” The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, and the number of options that will be forfeited prior to the completion of their vesting requirements. The Company estimates forfeitures based on historical experience with pre-vested forfeitures. To the extent actual forfeitures differ from the estimate, the difference is recorded to compensation expense in the period of the forfeiture. Fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations.
Revenue [Policy Text Block]	Revenue Recognition In accordance with ASC 606, five 1 Identify the contract(s) with a customer may not 2 Identify the performance obligations in the contract third not not one 3 Determine the transaction price not 4 Allocate the transaction price to the performance obligations in the contract not 5 Recognize revenue when (or as) the Company satisfies a performance obligation The Company recognizes revenue from its contracts with customers primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when control of the promised goods or services is transferred to a customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. For iCAD’s typical product revenue, control typically transfers upon shipment as title and risk of loss have passed to the customer. Services and supplies are considered to be transferred as the services are performed or over the term of the service or supply agreement. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Perpetual software licenses are accounted for as a single performance obligation and revenue is recognized at the point in time when ownership is transferred to the customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of revenue. The Company continues to provide for estimated warranty costs on original product warranties at the time of sale. Goods and Services Classifications Products Service Contracts 12 48 Supply and Source Usage Agreements Professional Services Other Significant Judgments The Company’s contracts with customers may may one may The Company may not Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes incremental costs of obtaining a contract with a customer as an asset if the Company expects the benefit of those costs to be longer than one one Right to Invoice Where applicable, the Company recognizes revenue from a contract with a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date and the amount to which the Company has a right to invoice. Sales and Other Similar Taxes The Company excludes sales taxes and similar taxes from the measurement of transaction price and ensures compliance with the disclosure requirements of ASC 235. Significant Financing Component The Company does not one Promised Goods or Services that are Immaterial in the Context of a Contract The Company assesses materiality of promised goods or services as performance obligations in the context of a contract and the Company does not 606 The Company does not one
Cost of Goods and Service [Policy Text Block]	Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house product warranty repairs, amortization of acquired technology and any applicable medical device tax.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty costs have not
Research and Development Expense, Policy [Policy Text Block]	Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials are expensed as incurred.
Advertising Cost [Policy Text Block]	Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2022, 2021 2020
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows the liability method under ASC Topic 740 Income Taxes 740” 740 December 31, 2022 December 31, 2021, December 31, 2022, not December 31, 2021, 13

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements (in thousands) as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,067 $ — $ — $ 15,067 Total Assets $ 15,067 $ — $ — $ 15,067 Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year ended December 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 12,492 $ 2,777 $ 15,269 Service contracts 7,310 1,540 8,850 Supply and source usage agreements — 1,643 1,643 Disposable applicators — 1,776 1,776 Professional services and other — 406 406 $ 19,802 $ 8,142 $ 27,944 Timing of Revenue Recognition Goods transferred at a point in time $ 12,545 $ 4,969 $ 17,514 Services transferred over time 7,257 3,173 10,430 $ 19,802 $ 8,142 $ 27,944 Sales Channels Direct sales force $ 12,468 $ 3,543 $ 16,011 OEM partners 7,334 — 7,334 Channel partners — 4,599 4,599 $ 19,802 $ 8,142 $ 27,944 Year ended December 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 15,661 $ 5,530 $ 21,191 Service contracts 6,358 1,608 7,966 Supply and source usage agreements — 2,340 2,340 Disposable applicators — 1,810 1,810 Professional services and other — 331 331 $ 22,019 $ 11,619 $ 33,638 Timing of Revenue Recognition Goods transferred at a point in time $ 15,584 $ 8,012 $ 23,596 Services transferred over time 6,435 3,607 10,042 $ 22,019 $ 11,619 $ 33,638 Sales Channels Direct sales force $ 14,713 $ 4,421 $ 19,134 OEM partners 7,306 — 7,306 Channel partners — 7,198 7,198 $ 22,019 $ 11,619 $ 33,638 Year ended December 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,291 $ 4,535 $ 20,826 Service contracts 5,661 1,333 6,994 Supply and source usage agreements — 1,804 1,804 Professional services — 29 29 Other 45 — 45 $ 21,997 $ 7,701 $ 29,698 Timing of Revenue Recognition Goods transferred at a point in time $ 16,332 $ 4,624 $ 20,956 Services transferred over time 5,665 3,077 8,742 $ 21,997 $ 7,701 $ 29,698 Sales Channels Direct sales $ 13,809 $ 3,773 $ 17,582 OEM partners 8,188 — 8,188 Channel partners — 3,928 3,928 $ 21,997 $ 7,701 $ 29,698
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at December 31, 2022 Balance at December 31, 2021 Receivables, which are included in ‘Trade accounts receivable’ $ 8,898 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 759 $ 1,895 Non-current contract assets, which are included in “other assets” $ 15 $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,758 $ 6,093
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Year Ended December 31, 2022 Year Ended December 31, 2021 Balance at beginning of period $ 6,093 $ 6,384 Deferral of revenue 12,129 12,315 Recognition of deferred revenue (11,464 ) (12,606 ) Balance at end of period $ 6,758 $ 6,093
Capitalized Contract Cost [Table Text Block]	Years Ended December 31, 2022 2021 Balance at beginning of period $ 302 $ 406 Deferral of costs to obtain a contract 120 249 Recognition of costs to obtain a contract (181 ) (353 ) Balance at end of period $ 241 $ 302

Note 6 - Net Loss Per Common _2

Note 6 - Net Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2022 2021 2020 Net loss $ (13,656 ) $ (11,245 ) $ (17,610 ) Basic shares used in the calculation of earnings per share 25,202 24,778 22,140 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 25,202 24,778 22,140 Net loss per share: Basic $ (0.54 ) $ (0.45 ) $ (0.80 ) Diluted $ (0.54 ) $ (0.45 ) $ (0.80 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2022 2021 2020 Common stock options 2,610,659 2,486,511 1,869,507 Restricted Stock — 875 29,166 2,610,659 2,487,386 1,898,673

Note 7 - Allowance for Doubtf_2

Note 7 - Allowance for Doubtful Accounts (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	2022 2021 2020 Balance at beginning of period $ 268 $ 111 $ 136 Additions charged to costs and expenses 732 167 94 Reductions (78 ) (10 ) (119 ) Balance at end of period $ 922 $ 268 $ 111

Note 8 - Inventories (Tables)

Note 8 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2022 December 31, 2021 Raw materials $ 2,658 $ 2,962 Work in process 101 173 Finished Goods 2,892 1,279 Inventory Gross 5,651 4,414 Inventory Reserve (262 ) (243 ) Inventory Net $ 5,389 $ 4,171

Note 9 - Goodwill and Intangi_2

Note 9 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Weighted average useful life 2022 2021 2020 (in years) Gross Carrying Amount Patents and licenses $ 626 $ 619 $ 595 5 Technology 8,257 8,257 8,257 10 Customer relationships 272 272 272 7 Tradename 259 259 259 10 Total amortizable intangible assets 9,414 9,407 9,383 Accumulated Amortization Patents and licenses $ 537 $ 534 $ 529 Technology 7,947 7,769 7,571 Customer relationships 189 162 135 Tradename 259 259 259 Total accumulated amortization 8,932 8,724 8,494 Total amortizable intangible assets, net $ 482 $ 683 $ 889
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated For the years ended amortization December 31: expense 2023 206 2024 121 2025 119 2026 18 2027 18 $ 482

Note 10 - Accrued and Other E_2

Note 10 - Accrued and Other Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	2022 2021 Accrued salary and related expenses $ 1,248 $ 2,016 Accrued accounts payable 2,913 2,838 Accrued professional fees 400 497 Other accrued expenses 120 291 $ 4,681 $ 5,642

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, Lease Cost Classification 2022 2021 Operating lease cost - Right of Use Operating expenses $ 859 $ 862 Operating lease cost - Variable Costs Operating expenses 277 186 Total $ 1,136 $ 1,048 Year Ended December 31, 2022 2021 Cash paid for operating cash flows from operating leases $ 931 $ 919 As of December 31, 2022 2021 Weighted-average remaining lease term of operating leases (in years) 3.77 1.33 Weighted-average discount rate for operating leases 6.98 % 5.50 %
Financing Lease and Lessee Operating Lease Liability Maturity [Table Text Block]	Year Ended December 31: Total 2023 781 2024 846 2025 848 2026 749 2027 685 Thereafter 172 Total lease payments 4,081 Less: effects of discounting (696 ) Total lease liabilities 3,385 Less: current portion of lease liabilities (582 ) Long-term lease liabilities $ 2,803

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Remaining Number of Weighted Average Contractual Term Shares Exercise Price (in years) Outstanding, December 31, 2020 1,869,507 $ 5.91 Granted 865,938 $ 16.33 Exercised (168,450 ) $ 6.10 Forfeited (80,484 ) $ 13.74 Outstanding, December 31, 2021 2,486,511 $ 9.27 5.42 Granted 836,500 $ 4.92 Exercised (73,500 ) $ 2.45 Forfeited (638,519 ) $ 11.45 Outstanding, December 31, 2022 2,610,992 $ 7.54 3.76 Exercisable at December 31, 2020 1,540,287 $ 5.55 Exercisable at December 31, 2021 1,619,855 $ 6.47 Exercisable at December 31, 2022 1,906,189 $ 7.59
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2022 2021 2020 Cost of revenue $ 3 $ 15 $ 30 Engineering and product development 220 356 376 Marketing and sales 518 785 657 General and administrative expense 945 1,627 1,781 $ 1,686 $ 2,783 $ 2,844
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2022 2021 2020 Average risk-free interest rate 2.29 % 0.42 % 0.65 % Expected dividend yield None None None Expected life (in years) 3.5 3.5 3.5 Expected volatility 66.30 - 72.04 % 65.57 - 67.42 % 50.17 - 66.04 % Weighted average fair value $ 2.33 $ 7.22 $ 4.37
Summary of Intrinsic Values of Option and Closing Market Price [Table Text Block]	Year Ended December 31, 2022 2021 2020 Outstanding $ — $ 3,820 $ 13,626 Exercisable $ — $ 3,730 $ 11,786 Exercised $ — $ 1,453 $ 1,037 Company’s stock price at December 31 $ 1.83 $ 7.20 $ 13.20
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Year Ended December 31, 2022 2021 2020 Beginning outstanding balance 875 29,166 150,909 Granted — 22,488 — Vested (875 ) (50,779 ) (118,077 ) Forfeited — — (3,666 ) Ending outstanding balance — 875 29,166

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2022 2021 2020 Current provision: Federal $ — $ — $ — State — — 37 Foreign — — — $ — $ — $ 37 Deferred provision: Federal $ — $ 1 $ 1 State — — — Foreign (116 ) — — $ (116 ) $ 1 $ 1 Total $ (116 ) $ 1 $ 38
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 2.5 % 5.2 % 2.4 % Net state impact of deferred rate change (1.0 )% 0.8 % (0.7 )% Stock compensation expense (0.7 )% 1.3 % 0.9 % Other permanent differences (0.4 )% (0.1 )% (0.1 )% Change in valuation allowance (13.7 )% (24.4 )% (13.4 )% Tax credits 2.0 % 3.1 % 1.4 % Accrual to tax return 0.0 % (1.4 )% 0.0 % FV Mark to market on convertible notes 0.0 % 0.0 % (9.0 )% Foreign Rate Differential 0.0 % 0.0 % 0.0 % True Ups - NOL Expiration/162(m) limits (8.9 )% (5.4 )% (2.8 )% Effective income tax 0.8 % 0.1 % (0.3 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2022 2021 Inventory (Section 263A) $ 311 $ 276 Inventory reserves 61 61 Bad debt reserves 215 67 Other accruals 813 854 Deferred revenue 129 107 Accumulated depreciation/amortization 17 8 Stock options 1,108 795 Developed technology 976 1,242 Tax credits 4,427 4,176 NOL carryforward 38,234 38,383 Lease Liability 792 — Section 174 R&D 1,749 290 Deferred tax assets 48,832 46,259 Valuation allowance (47,930 ) (45,994 ) Right of Use Asset (786 ) (265 ) Goodwill tax amortization (6 ) (5 ) Net deferred tax asset (liability) $ 110 $ (5 )

Note 14 - Segment Reporting (Ta

Note 14 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2022 2021 2020 Segment revenues: Detection $ 19,802 $ 22,019 $ 21,997 Therapy 8,142 11,619 7,701 Total Revenue $ 27,944 $ 33,638 $ 29,698 Segment gross profit: Detection $ 16,824 $ 18,510 $ 17,856 Therapy 2,988 5,733 3,498 Total gross profit $ 19,812 $ 24,243 $ 21,354 Segment operating income (loss): Detection $ 902 $ 1,563 $ 2,719 Therapy (3,767 ) (1,835 ) (3,028 ) Segment operating income (loss) $ (2,865 ) $ (272 ) $ (309 ) General administrative $ (10,852 ) $ (10,460 ) $ (9,079 ) Interest expense (10 ) (141 ) (476 ) Loss on extinguishment of debt — (386 ) (341 ) Other income (45 ) 15 97 Fair value of convertible debentures — — (7,464 ) Loss before income tax $ (10,907 ) $ (10,972 ) $ (17,263 )
Schedule of Segment Related Depreciation and Amortization Expense [Table Text Block]	Year Ended December 31, 2022 2021 2020 Detection depreciation and amortization Depreciation $ 109 $ 123 $ 115 Amortization $ 134 $ 158 164 Therapy depreciation and amortization Depreciation $ 129 $ 129 $ 124 Amortization $ 73 $ 73 128
Revenue from External Customers by Geographic Areas [Table Text Block]	Percent of Export sales Region 2022 2021 2020 Europe 24 % 39 % 45 % Taiwan 14 % 12 % 13 % Israel 13 % 0 % 0 % Bangladesh 8 % 0 % 0 % Malaysia 4 % 0 % 0 % Canada 1 % 3 % 5 % China 18 % 35 % 22 % Australia 3 % 0 % 0 % Other 15 % 11 % 15 % Total 100 % 100 % 100 % Total Export Revenue $ 6,976 $ 7,527 $ 6,081 Percent of Export sales Region 2022 2021 2020 France 45 % 47 % 41 % Italy 11 % 5 % 8 % Spain 10 % 17 % 17 % Germany 9 % 4 % 12 % Belgium 8 % 0 % 0 % Switzerland 6 % 8 % 0 % Sweden 4 % 0 % 0 % United Kingdom 1 % 4 % 6 % Russia 0 % 8 % 0 % % % % % % %

Note 16 - Notes Payable (Tables

Note 16 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 — Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A Probability of default event 1 0.45 % N/A Utilization of Forced Conversion (if available) 1 100.00 % 100.00 % Exercise of Default Redemption (if available) 1 100.00 % N/A Effective discount rate 1 18.52 % N/A
Convertible Debentures Fair Value and Principal Value [Table Text Block]	Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970

Note 1 - Organization and Bus_2

Note 1 - Organization and Business (Details Textual)	12 Months Ended
	Dec. 31, 2022
Number of Operating Segments	2

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Unbilled Receivables, Current	$ 200,000
Goodwill, Impairment Loss	0	$ 0
Impairment, Long-Lived Asset, Held-for-Use, Total	0	0
Advertising Expense	$ 659,000	$ 689,000	$ 274,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	10 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Concentration Risk, Percentage	25%
Export Revenue [Member] | Geographic Concentration Risk [Member]
Concentration Risk, Percentage	100%	100%	100%
Export Revenue [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Concentration Risk, Percentage	24%	39%	45%

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Nonrecurring [Member]
Assets, Fair Value Disclosure, Total	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure, Total	$ 0	$ 0

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0	$ 0
Fair Value, Recurring [Member]
Assets, fair value	15,067	30,573
Fair Value, Recurring [Member] | Money Market Funds [Member]
Assets, fair value	15,067	30,573
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	15,067	30,573
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets, fair value	15,067	30,573
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Assets, fair value	$ 0	$ 0

Note 5 - Revenue (Details Textu

Note 5 - Revenue (Details Textual) $ in Millions	Dec. 31, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year

Note 5 - Revenue - Revenues Dis

Note 5 - Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from contracts with customers	$ 27,944	$ 33,638	$ 29,698
Direct Sales Force [Member]
Revenue from contracts with customers	16,011	19,134
Direct Sales [Member]
Revenue from contracts with customers			17,582
OEM Partners [Member]
Revenue from contracts with customers	7,334	7,306	8,188
Channel Partners [Member]
Revenue from contracts with customers	4,599	7,198	3,928
Transferred at Point in Time [Member]
Revenue from contracts with customers	17,514	23,596	20,956
Transferred over Time [Member]
Revenue from contracts with customers	10,430	10,042	8,742
Product [Member]
Revenue from contracts with customers	15,269	21,191	20,826
Service Contracts [Member]
Revenue from contracts with customers	8,850	7,966	6,994
Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	1,643	2,340	1,804
Disposable Applicators [Member]
Revenue from contracts with customers	1,776	1,810
Professional Services [Member]
Revenue from contracts with customers	406	331	29
Other [Member]
Revenue from contracts with customers			45
Detection [Member]
Revenue from contracts with customers	19,802	22,019	21,997
Detection [Member] | Direct Sales Force [Member]
Revenue from contracts with customers	12,468	14,713
Detection [Member] | Direct Sales [Member]
Revenue from contracts with customers			13,809
Detection [Member] | OEM Partners [Member]
Revenue from contracts with customers	7,334	7,306	8,188
Detection [Member] | Channel Partners [Member]
Revenue from contracts with customers	0	0	0
Detection [Member] | Transferred at Point in Time [Member]
Revenue from contracts with customers	12,545	15,584	16,332
Detection [Member] | Transferred over Time [Member]
Revenue from contracts with customers	7,257	6,435	5,665
Detection [Member] | Product [Member]
Revenue from contracts with customers	12,492	15,661	16,291
Detection [Member] | Service Contracts [Member]
Revenue from contracts with customers	7,310	6,358	5,661
Detection [Member] | Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	0	0	0
Detection [Member] | Disposable Applicators [Member]
Revenue from contracts with customers	0	0
Detection [Member] | Professional Services [Member]
Revenue from contracts with customers	0	0	0
Detection [Member] | Other [Member]
Revenue from contracts with customers			45
Therapy [Member]
Revenue from contracts with customers	8,142	11,619	7,701
Therapy [Member] | Direct Sales Force [Member]
Revenue from contracts with customers	3,543	4,421
Therapy [Member] | Direct Sales [Member]
Revenue from contracts with customers			3,773
Therapy [Member] | OEM Partners [Member]
Revenue from contracts with customers	0	0	0
Therapy [Member] | Channel Partners [Member]
Revenue from contracts with customers	4,599	7,198	3,928
Therapy [Member] | Transferred at Point in Time [Member]
Revenue from contracts with customers	4,969	8,012	4,624
Therapy [Member] | Transferred over Time [Member]
Revenue from contracts with customers	3,173	3,607	3,077
Therapy [Member] | Product [Member]
Revenue from contracts with customers	2,777	5,530	4,535
Therapy [Member] | Service Contracts [Member]
Revenue from contracts with customers	1,540	1,608	1,333
Therapy [Member] | Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	1,643	2,340	1,804
Therapy [Member] | Disposable Applicators [Member]
Revenue from contracts with customers	1,776	1,810
Therapy [Member] | Professional Services [Member]
Revenue from contracts with customers	$ 406	$ 331	29
Therapy [Member] | Other [Member]
Revenue from contracts with customers			$ 0

Note 5 - Revenue - Summary of R

Note 5 - Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Receivables, which are included in ‘Trade accounts receivable’	$ 8,898	$ 8,891
Current contract assets, which are included in “Prepaid and other assets”	759	1,895
Non-current contract assets, which are included in “other assets”	15	844
Contract liabilities, which are included in “Deferred revenue”	$ 6,758	$ 6,093	$ 6,384

Note 5 - Revenue - Summary of C

Note 5 - Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance at beginning of period	$ 6,093	$ 6,384
Deferral of revenue	12,129	12,315
Recognition of deferred revenue	(11,464)	(12,606)
Balance at end of period	$ 6,758	$ 6,093

Note 5 - Revenue - Schedule of

Note 5 - Revenue - Schedule of Changes of Capitalized Costs to Obtain Contract (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 302	$ 406
Deferral of costs to obtain a contract	120	249
Recognition of costs to obtain a contract	(181)	(353)
Balance	$ 241	$ 302

Note 6 - Net Loss Per Common _3

Note 6 - Net Loss Per Common Share - Calculation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (13,656)	$ (11,245)	$ (17,610)
Basic shares used in the calculation of earnings per share (in shares)	25,202	24,778	22,140
Stock options (in shares)	0	0	0
Restricted stock (in shares)	0	0	0
Diluted shares used in the calculation of earnings per share (in shares)	25,202	24,778	22,140
Basic (in dollars per share)	$ (0.54)	$ (0.45)	$ (0.80)
Diluted (in dollars per share)	$ (0.54)	$ (0.45)	$ (0.80)

Note 6 - Net Loss Per Common _4

Note 6 - Net Loss Per Common Share - Schedule of Anti-dilutive Shares Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common stock options, warrants and restricted stock (in shares)	2,610,659	2,487,386	1,898,673
Share-Based Payment Arrangement, Option [Member]
Common stock options, warrants and restricted stock (in shares)	2,610,659	2,486,511	1,869,507
Restricted Stock [Member]
Common stock options, warrants and restricted stock (in shares)	0	875	29,166

Note 7 - Allowance for Doubtf_3

Note 7 - Allowance for Doubtful Accounts - Schedule of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 268	$ 111	$ 136
Additions charged to costs and expenses	732	167	94
Reductions	(78)	(10)	(119)
Balance	$ 922	$ 268	$ 111

Note 8 - Inventory - Schedule o

Note 8 - Inventory - Schedule of Current Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Raw materials	$ 2,658	$ 2,962
Work in process	101	173
Finished Goods	2,892	1,279
Inventory Gross	5,651	4,414
Inventory Reserve	(262)	(243)
Inventory Net	$ 5,389	$ 4,171

Note 9 - Goodwill and Intangi_3

Note 9 - Goodwill and Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill, Ending Balance	$ 8,362,000	$ 8,362,000
Goodwill, Period Increase (Decrease), Total	0	0
Goodwill, Impairment Loss	0	0
Goodwill, Other Increase (Decrease)	0	0
Amortization of Intangible Assets	211,000	230,000	$ 309,000
Detection [Member]
Goodwill, Ending Balance	$ 8,362,000	$ 8,362,000

Note 9 - Goodwill and Intangi_4

Note 9 - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Gross Carrying Amount	$ 9,414	$ 9,407	$ 9,383
Intangible assets, accumulated amortization	8,932	8,724	8,494
Intangible assets, net of accumulated amortization of $8,932 in 2022 and $8,724 in 2021	482	683	889
Patents and Licenses [Member]
Gross Carrying Amount	$ 626	619	595
Weighted average useful life (Year)	5 years
Intangible assets, accumulated amortization	$ 537	534	529
Developed Technology Rights [Member]
Gross Carrying Amount	$ 8,257	8,257	8,257
Weighted average useful life (Year)	10 years
Intangible assets, accumulated amortization	$ 7,947	7,769	7,571
Customer Relationships [Member]
Gross Carrying Amount	$ 272	272	272
Weighted average useful life (Year)	7 years
Intangible assets, accumulated amortization	$ 189	162	135
Trade Names [Member]
Gross Carrying Amount	$ 259	259	259
Weighted average useful life (Year)	10 years
Intangible assets, accumulated amortization	$ 259	$ 259	$ 259

Note 9 - Goodwill and Intangi_5

Note 9 - Goodwill and Intangible assets - Schedule of Expected Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
2023	$ 206
2024	121
2025	119
2026	18
2027	18
Intangible Assets, Net (Excluding Goodwill), Total	$ 482	$ 683	$ 889

Note 10 - Accrued and Other E_3

Note 10 - Accrued and Other Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued salary and related expenses	$ 1,248	$ 2,016
Accrued accounts payable	2,913	2,838
Accrued professional fees	400	497
Other accrued expenses	120	291
Accounts Payable and Accrued Liabilities, Current, Total	$ 4,681	$ 5,642

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Nov. 30, 2022	May 31, 2022	Oct. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Increase (Decrease) in Operating Lease Liability				$ (767,000)	$ (778,000)	$ (752,000)
California Facility Lease [Member]
Increase (Decrease) in Operating Lease Liability		$ 2,400,000
Increase (Decrease) in Operating Lease Right of Use Assets		$ 2,400,000
Nashua, NH Office Lease [Member]
Increase (Decrease) in Operating Lease Liability	$ 600,000
Increase (Decrease) in Operating Lease Right of Use Assets	$ 600,000
Nashua Warehouse Lease [Member]
Increase (Decrease) in Operating Lease Liability			$ 79,000
Increase (Decrease) in Operating Lease Right of Use Assets			$ 79,000

Note 11 - Leases - Schedule of

Note 11 - Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating lease cost - Right of Use	$ 859	$ 862
Operating lease cost - Variable Costs	277	186
Total	1,136	1,048
Cash paid for operating cash flows from operating leases	$ 931	$ 919
Weighted-average remaining lease term of operating leases (in years) (Year)	3 years 9 months 7 days	1 year 3 months 29 days
Weighted-average discount rate for operating leases	6.98%	5.50%

Note 11 - Leases - Summary of D

Note 11 - Leases - Summary of Detained Information of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 781
2024	846
2025	848
2026	749
2027	685
Thereafter	172
Total lease payments	4,081
Less: effects of discounting	(696)
Total lease liabilities	3,385
Less: current portion of lease liabilities	(582)	$ (889)
Long-term lease liabilities	$ 2,803	$ 266

Note 12 - Stockholders' Equit_2

Note 12 - Stockholders' Equity (Details Textual) - USD ($)				12 Months Ended
	Mar. 02, 2021	Dec. 17, 2020	Apr. 27, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		470,704	1,562,500	73,500	168,450
Shares Issued, Price Per Share (in dollars per share)			$ 8
Gross Proceeds From Issuance of Common Stock		$ 6,600,000	$ 12,500,000
Proceeds from Issuance of Common Stock		$ 6,100,000	12,300,000	$ 0	$ 23,229,000	$ 18,285,000
Stock Issued During Period, Value, New Issues			$ 25,000,000		$ 23,229,000	$ 18,284,000
Partners' Capital Account, Units, Sale of Units, Total (in shares)	1,393,738
Sale of Stock, Price Per Share (in dollars per share)	$ 18
Partners' Capital Account, Public Sale of Units Net of Offering Costs	$ 23,200,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 1,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 10 months 24 days
Stock Plans [Member]
Minimum Expected Percentage of Options Exercise Price to Fair Market Value of Common Stock				100%
The 2012 Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				2,016
The 2016 Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				1,448,471
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				4,700,000	2,600,000
ESPP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				950,000
Percentage of Voting Right not Eligible for ESPP				5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate				15%
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date				85%
Share Based Compensation Arrangement By Share Based Payment Award, Maximum Amount of Shares Per Employee				$ 25,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)				46,096	24,786
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				836,824
Underwriting Agreement [Member]
Sale of Stock, Price Per Share (in dollars per share)	$ 16.92
Reimbursement of Expenses in Connection With The Offering	$ 125,000

Note 12 - Stockholders' Equit_3

Note 12 - Stockholders' Equity - Summary of Stock Option Activity for Stock Option Plan (Details) - $ / shares			12 Months Ended
	Dec. 17, 2020	Apr. 27, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Outstanding, shares (in shares)			2,486,511	1,869,507
Outstanding, weighted average exercise price (in dollars per share)			$ 9.27	$ 5.91
Granted, shares (in shares)			836,500	865,938
Granted, weighted average exercise price (in dollars per share)			$ 4.92	$ 16.33
Exercised, shares (in shares)	(470,704)	(1,562,500)	(73,500)	(168,450)
Exercised, weighted average exercise price (in dollars per share)			$ 2.45	$ 6.10
Forfeited, shares (in shares)			(638,519)	(80,484)
Forfeited, weighted average exercise price (in dollars per share)			$ 11.45	$ 13.74
Outstanding, weighted average exercise price (in dollars per share)			$ 7.54	$ 9.27	$ 5.91
Outstanding, weighted average remaining contractual term (Year)			3 years 9 months 3 days	5 years 5 months 1 day
Outstanding, shares (in shares)			2,610,992	2,486,511	1,869,507
Outstanding, weighted average exercise price (in dollars per share)			$ 7.54	$ 9.27	$ 5.91
Exercisable, shares (in shares)			1,906,189	1,619,855	1,540,287
Exercisable, weighted average exercise price (in dollars per share)			$ 7.59	$ 6.47	$ 5.55

Note 12 - Stockholders' Equit_4

Note 12 - Stockholders' Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allocated share-based compensation expense	$ 1,686	$ 2,783	$ 2,844
Cost of Sales [Member]
Allocated share-based compensation expense	3	15	30
Engineering and Product Development [Member]
Allocated share-based compensation expense	220	356	376
Selling and Marketing Expense [Member]
Allocated share-based compensation expense	518	785	657
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 945	$ 1,627	$ 1,781

Note 12 - Stockholders' Equit_5

Note 12 - Stockholders' Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Average risk-free interest rate	2.29%	0.42%	0.65%
Expected dividend yield	0%	0%	0%
Expected life (in years) (Year)	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average fair value (in dollars per share)	$ 2.33	$ 7.22	$ 4.37
Minimum [Member]
Expected volatility	66.30%	65.57%	50.17%
Maximum [Member]
Expected volatility	72.04%	67.42%	66.04%

Note 12 - Stockholders' Equit_6

Note 12 - Stockholders' Equity - Summary of Intrinsic Values of Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Outstanding	$ 0	$ 3,820	$ 13,626
Exercisable	0	3,730	11,786
Exercised	$ 0	$ 1,453	$ 1,037
Company’s stock price at December 31 (in dollars per share)	$ 1.83	$ 7.20	$ 13.20

Note 12 - Stockholders' Equit_7

Note 12 - Stockholders' Equity - Summary of Restricted Stock Activity for Equity Incentive Plans (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Beginning outstanding balance (in shares)	875	29,166	150,909
Granted (in shares)	0	22,488	0
Vested (in shares)	(875)	(50,779)	(118,077)
Forfeited (in shares)	0	0	(3,666)
Ending outstanding balance (in shares)	0	875	29,166

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets, Tax Credit Carryforwards, Total	$ 4,427,000	$ 4,176,000
Unrecognized Tax Benefits, Ending Balance	0	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0
Xoft Inc [Member]
Net Operating Loss, Limitations on Use	4,600,000
Net Operating Loss Carryforwards, Limitation on Use	656,000
Future Income Tax Liabilities Offset With Operation Loss Carryforward	4,400,000
Deferred Tax Assets, Tax Credit Carryforwards, Total	1,500,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	158,400,000
Domestic Tax Authority [Member] | Expires Between 2023 and 2037 [Member]
Operating Loss Carryforwards	116,300,000
Domestic Tax Authority [Member] | Indefinite Period [Member]
Operating Loss Carryforwards	42,100,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards	500,000
Operating Loss Carryforwards, Valuation Allowance	$ 0

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal	$ 0	$ 0	$ 0
State	0	0	37
Foreign	0	0	0
Current Income Tax Expense (Benefit), Total	0	0	37
Federal	0	1	1
State	0	0	0
Foreign	(116)	0	0
Deferred Income Tax Expense (Benefit), Total	(116)	1	1
Total	$ (116)	$ 1	$ 38

Note 13 - Income Taxes - Summar

Note 13 - Income Taxes - Summary of Effective and the Federal Statutory Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal statutory rate	21%	21%	21%
State income taxes, net of federal benefit	2.50%	5.20%	2.40%
Net state impact of deferred rate change	(1.00%)	0.80%	(0.70%)
Stock compensation expense	(0.70%)	1.30%	0.90%
Other permanent differences	(0.40%)	(0.10%)	(0.10%)
Change in valuation allowance	(13.70%)	(24.40%)	(13.40%)
Tax credits	2%	3.10%	1.40%
Accrual to tax return	0%	(1.40%)	0%
FV Mark to market on convertible notes	0%	0%	(9.00%)
Foreign Rate Differential	0%	0%	0%
True Ups - NOL Expiration/162(m) limits	(8.90%)	(5.40%)	(2.80%)
Effective income tax	0.80%	0.10%	(0.30%)

Note 13 - Income Taxes - Deferr

Note 13 - Income Taxes - Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory (Section 263A)	$ 311	$ 276
Inventory reserves	61	61
Bad debt reserves	215	67
Other accruals	813	854
Deferred revenue	129	107
Accumulated depreciation/amortization	17	8
Stock options	1,108	795
Developed technology	976	1,242
Tax credits	4,427	4,176
NOL carryforward	38,234	38,383
Lease Liability	792	0
Section 174 R&D	1,749	290
Deferred tax assets	48,832	46,259
Valuation allowance	(47,930)	(45,994)
Right of Use Asset	(786)	(265)
Goodwill tax amortization	(6)	(5)
Net deferred tax asset (liability)	$ 110
Net deferred tax asset (liability)		$ (5)

Note 14 - Segment Reporting (De

Note 14 - Segment Reporting (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Number of Reportable Segments	2
Accounts Receivable, after Allowance for Credit Loss, Total	$ 8,898	$ 8,891
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Non-US [Member]
Revenues, Total	$ 7,000	$ 7,500	$ 6,100
Concentration Risk, Percentage	25%	22%	20%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 4,000	$ 3,100
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Revenues, Total	$ 4,400	$ 4,800	$ 5,000
Concentration Risk, Percentage	16%	14%	17%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Four OEM Partners [Member]
Concentration Risk, Percentage	21%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Four OEM Partners [Member] | Detection [Member]
Concentration Risk, Percentage	29%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Detection OEM Partners [Member]
Concentration Risk, Percentage	26%	26%	28%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Detection OEM Partners [Member] | Detection [Member]
Concentration Risk, Percentage	37%	40%	37%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Major Direct Customer [Member]
Revenues, Total	$ 8,000
Concentration Risk, Percentage	2%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Concentration Risk, Percentage	11%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 1,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | OEM Partners [Member]
Concentration Risk, Percentage	22%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 2,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Four Largest Therapy Customers [Member]
Concentration Risk, Percentage	24%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 2,100
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Largest Detection Direct Customer [Member]
Concentration Risk, Percentage	17%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 1,500
Accounts Receivable [Member] | Customer Concentration Risk [Member] | OEM, Four Largest Therapy, and Largest Detection Customers [Member]
Concentration Risk, Percentage	40%
Accounts Receivable, after Allowance for Credit Loss, Total	$ 3,600

Note 14 - Segment Reporting - S

Note 14 - Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 27,944	$ 33,638	$ 29,698
Total gross profit	19,812	24,243	21,354
General administrative	(11,234)	(10,406)	(9,117)
Interest expense	(10)	(141)	(476)
Loss on extinguishment of debt	0	(386)	(341)
Other	(45)	0	0
Loss on fair value of convertible debentures	0	0	(7,464)
Loss before income tax expense	(13,772)	(11,244)	(17,572)
Operating Segments [Member]
Revenue	27,944	33,638	29,698
Total gross profit	19,812	24,243	21,354
Segment operating income (loss)	(2,865)	(272)	(309)
General administrative	(10,852)	(10,460)	(9,079)
Interest expense	(10)	(141)	(476)
Loss on extinguishment of debt	0	(386)	(341)
Other	(45)	15	97
Loss on fair value of convertible debentures	0	0	(7,464)
Loss before income tax expense	(10,907)	(10,972)	(17,263)
Detection [Member] | Operating Segments [Member]
Revenue	19,802	22,019	21,997
Total gross profit	16,824	18,510	17,856
Segment operating income (loss)	902	1,563	2,719
Therapy [Member] | Operating Segments [Member]
Revenue	8,142	11,619	7,701
Total gross profit	2,988	5,733	3,498
Segment operating income (loss)	$ (3,767)	$ (1,835)	$ (3,028)

Note 14 - Segment Reporting -_2

Note 14 - Segment Reporting - Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Depreciation	$ 310	$ 327	$ 268
Amortization	211	230	309
Detection [Member] | Operating Segments [Member]
Depreciation	109	123	115
Amortization	134	158	164
Therapy [Member] | Operating Segments [Member]
Depreciation	129	129	124
Amortization	$ 73	$ 73	$ 128

Note 14 - Segment Reporting -_3

Note 14 - Segment Reporting - Summary of Concentration of Revenue by Geographic Area (Details) - Export Revenue [Member] - Geographic Concentration Risk [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Percent of Export sales	100%	100%	100%
Total Export Revenue	$ 6,976	$ 7,527	$ 6,081
Europe [Member]
Percent of Export sales	24%	39%	45%
FRANCE
Percent of Export sales	45%	47%	41%
TAIWAN
Percent of Export sales	14%	12%	13%
ITALY
Percent of Export sales	11%	5%	8%
ISRAEL
Percent of Export sales	13%	0%	0%
SPAIN
Percent of Export sales	10%	17%	17%
BANGLADESH
Percent of Export sales	8%	0%	0%
GERMANY
Percent of Export sales	9%	4%	12%
MALAYSIA
Percent of Export sales	4%	0%	0%
BELGIUM
Percent of Export sales	8%	0%	0%
CANADA
Percent of Export sales	1%	3%	5%
SWITZERLAND
Percent of Export sales	6%	8%	0%
CHINA
Percent of Export sales	18%	35%	22%
SWEDEN
Percent of Export sales	4%	0%	0%
AUSTRALIA
Percent of Export sales	3%	0%	0%
UNITED KINGDOM
Percent of Export sales	1%	4%	6%
Other Geographic Locations [Member]
Percent of Export sales	15%	11%	15%
RUSSIAN FEDERATION
Percent of Export sales	0%	8%	0%

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Details Textual) - USD ($)		3 Months Ended	12 Months Ended
	Apr. 13, 2021	Jun. 30, 2021	Dec. 31, 2022	Jan. 30, 2017	Dec. 31, 2016
Purchase Obligation, Total			$ 4,600,000
Minimum Annual Royalty Payment			250,000
Fair Value of Patent License			100,000
Minimum Royalty Obligations			$ 200,000
Litigation Settlement, Amount Awarded to Other Party	$ 85,000
Litigation Settlement, Amount Awarded from Other Party		$ 50,000
Litigation Settlement, Expense		$ 93,000
VersaVue Software and DynaCAD Product and Related Assets [Member]
Disposal Group, Including Discontinued Operation, Consideration					$ 3,200,000
Disposal Group Including Discontinued Operation Holdback Reserve				$ 350,000
Disposal Group Including Discontinued Operation Consideration, Net of Holdback Reserve				$ 2,900,000

Note 16 - Notes Payable (Detail

Note 16 - Notes Payable (Details Textual)				1 Months Ended	12 Months Ended
	Apr. 27, 2021 USD ($)	Mar. 30, 2020 USD ($)	Feb. 21, 2020 USD ($) $ / shares	Mar. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Dec. 20, 2018 USD ($)	Aug. 07, 2017 USD ($)
Repayments of Lines of Credit					$ 0	$ 0	$ 2,775,000
Gain (Loss) on Extinguishment of Debt, Total					$ 0	$ (386,000)	(341,000)
Convertible Debt, Fair Value Disclosures			$ 21,164,000					$ 13,642,000
Convertible Debt [Member]
Debt Instrument, Face Amount									$ 7,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 4
Debt Instrument, Convertible, Number of Equity Instruments			1,742,500
Gain (Loss) on Sales of Loans, Net, Total							$ (7,500,000)
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | shares							1,816,466
Convertible Debt, Fair Value Disclosures							$ 21,200,000
Silicon Valley Bank [Member]
Gain (Loss) on Extinguishment of Debt, Total				$ (341,000)
Final Payment of Loan		$ 510,000		185,000
Termination Loans		114,000		114,000
Unamortized Debt Issuance Expense				$ 42,000
Other Costs		10,000
Silicon Valley Bank [Member] | Revolving Credit Facility [Member]
Long-Term Line of Credit, Total		5,000,000								$ 4,000,000
Repayments of Lines of Credit	$ 7,354,283
Western Alliance Bank [Member]
Gain (Loss) on Extinguishment of Debt, Total	(386,000)
Debt Prepayment Cost	140,000
Final Payment of Loan	122,000
Termination Loans	65,000
Unamortized Debt Issuance Expense	$ 58,000
Term Loan A [Member] | Silicon Valley Bank [Member]
Long-Term Line of Credit, Total		$ 7,000,000								$ 6,000,000
Make Whole Provision [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount			$ 697,000
Debt Instrument, Convertible, Number of Equity Instruments			76,966

Note 16 - Notes Payable - Sched

Note 16 - Notes Payable - Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures (Details)		Feb. 21, 2020	Dec. 31, 2019
Measurement Input, Share Price [Member]
Debt Instrument Measurement Input		11.64	7.77
Measurement Input, Conversion Price [Member]
Debt Instrument Measurement Input		4	4
Measurement Input, Expected Term [Member]
Debt Instrument Measurement Input			1.97
Measurement Input, Price Volatility [Member]
Debt Instrument Measurement Input			49
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument Measurement Input			1.57
Measurement Input, Default Rate [Member]
Debt Instrument Measurement Input	[1]		0.45
Measurement Input, Utilization of Forced Conversion [Member]
Debt Instrument Measurement Input	[1]	100	100
Measurement Input, Exercise of Default Redemption [Member]
Debt Instrument Measurement Input	[1]		100
Measurement Input, Discount Rate [Member]
Debt Instrument Measurement Input	[1]		18.52
[1]Represents a Level 3 unobservable input, as defined in Note 4 - Fair Value Measurements, below.

Note 16 - Notes Payable - Sch_2

Note 16 - Notes Payable - Schedule of Fair Value and Principal Value of Convertible Debentures (Details) - USD ($) $ in Thousands	Feb. 21, 2020	Dec. 31, 2019
Fair value, in accordance with fair value option	$ 21,164	$ 13,642
Principal value outstanding	$ 6,970	$ 6,970

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	90%
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.6	$ 0.5

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Millions	Mar. 20, 2023 USD ($)
Restructuring and Related Cost, Expected Cost, Total	$ 0.3
Xoft Inc [Member]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	28%
Restructuring and Related Cost, Number of Positions Eliminated	23
Therapy [Member]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	50%
Restructuring and Related Cost, Number of Positions Eliminated	12